Abstract
Objective. To consider the evidence-based approaches to treating virus-associated lung tissue lesions, the rationale for using the Markov model to evaluate the clinical and economic efficacy of interleukin (IL)-6 (IL-6) receptor inhibitors in patients with COVID-19. Subjects and methods. To evaluate the clinical and economic effectiveness of using the receptor inhibitors in COVID-19 patients, the investigators formed two groups: 1) 187 patients received the standard therapy; 2) 104 patients had IL-6 receptor inhibitors in addition to the standard therapy. Results and conclusion. The logistic regression method was used to determine the need for prescribing these drugs depending on the individual characteristics of patients, the key points were the length of a patient's stay in the intensive care unit, as well as the duration of oxygen support. In the context of new challenges to the healthcare system, it is necessary to further search for comprehensive methods of monitoring the condition and prognosis with promising ways to assess the validity of using therapeutic procedures and drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
